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Background: Bivalirudin and radial access use is associated with reduced percutaneous coronary intervention (PCI)-related bleeding. The 
comparative effectiveness of each among patients with varied bleeding risk is not known. 
Methods: Analysis of patients from the National Cardiovascular Data Registry® CathPCI registry® reported between 2004-2008. Major bleeding 
events required transfusion, prolonged hospital stay, and/or hemoglobin drop >3 g/dL. The validated NCDR bleeding risk model was used to stratify 
patients into low (3%) categories for peri-PCI bleeding. Propensity scoring was applied to develop a 3:1 match (0.5%) for non-radial and radial use, 
respectively.
Results: Among 95,511 propensity matched patients, there were 1,679 (1.8%) bleeding events. Overall radial access was associated with ~50% 
fewer bleeding events than nonuse in all patients (1% vs 2%, P<0.001) and each risk group (low: 0.3% vs 0.7%; intermediate: 0.9% vs 1.9%; high: 
2.7% vs 5.3%, all P<0.001). Compared with no therapy, bleeding events declined with the use of bivalirudin or radial access and were lowest when 
both therapies were combined, primarily driven by fewer events in high risk patients (Figure). 
Conclusions: Use of bivalirudin or radial access was associated with reduced bleeding events compared with no therapy. Combined use 
of both therapies was associated with the fewest overall bleeding events most notably in patients at intermediate or high risk for bleeding.
